about
Centrosome-associated regulators of the G(2)/M checkpoint as targets for cancer therapySynthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancerTwo 4N cell-cycle arrests contribute to cisplatin-resistanceMartini: using literature keywords to compare gene setsA phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer.DNA damage-induced cell death is enhanced by progression through mitosisPhase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m(2) every 21 days in patients with cancerNetwork architecture of signaling from uncoupled helicase-polymerase to cell cycle checkpoints and trans-lesion DNA synthesis.New molecular targets in radiotherapy: DNA damage signalling and repair in targeted and non-targeted cellsThe HSP90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancer.Experimental therapy of ovarian cancer with synthetic makaluvamine analog: in vitro and in vivo anticancer activity and molecular mechanisms of action.Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights.New insights into checkpoint kinase 1 in the DNA damage response signaling network.Gain of cellular adaptation due to prolonged p53 impairment leads to functional switchover from p53 to p73 during DNA damage in acute myeloid leukemia cellsCharacterization of DDRI-18 (3,3'-(1H,3'H-5,5'-bibenzo[d]imidazole-2,2'-diyl)dianiline), a novel small molecule inhibitor modulating the DNA damage response.PUMA induction by FoxO3a mediates the anticancer activities of the broad-range kinase inhibitor UCN-01.Disruption of Src function potentiates Chk1-inhibitor-induced apoptosis in human multiple myeloma cells in vitro and in vivo.Phosphoproteomic analysis of signaling pathways in head and neck squamous cell carcinoma patient samplesNatura-alpha targets forkhead box m1 and inhibits androgen-dependent and -independent prostate cancer growth and invasion.Discovery of novel checkpoint kinase 1 inhibitors by virtual screening based on multiple crystal structuresTargeted mutations in the ATR pathway define agent-specific requirements for cancer cell growth and survivalCheckpoint kinase1 (CHK1) is an important biomarker in breast cancer having a role in chemotherapy responseRational Combinations of Targeted Agents in AMLTargeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models.A supported liquid extraction LC-MS/MS method for determination of concentrations of GDC-0425, a small molecule Checkpoint kinase 1 inhibitor, in human plasma.Differential regulation of p21 (waf1) protein half-life by DNA damage and Nutlin-3 in p53 wild-type tumors and its therapeutic implications.Caspase-9 mediates Puma activation in UCN-01-induced apoptosis.Cisplatin sensitivity mediated by WEE1 and CHK1 is mediated by miR-155 and the miR-15 family.New combination therapies with cell-cycle agentsMolecular targets and mechanisms of radiosensitization using DNA damage response pathways.Interruption of the Ras/MEK/ERK signaling cascade enhances Chk1 inhibitor-induced DNA damage in vitro and in vivo in human multiple myeloma cellsPARP and CHK inhibitors interact to cause DNA damage and cell death in mammary carcinoma cellsPhase I study of UCN-01 and perifosine in patients with relapsed and refractory acute leukemias and high-risk myelodysplastic syndrome.G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancerParticipation of DNA repair in the response to 5-fluorouracil.High-throughput kinase profiling as a platform for drug discovery.CHK1 inhibition as a strategy for targeting Fanconi Anemia (FA) DNA repair pathway deficient tumors90-kDa heat shock protein inhibition abrogates the topoisomerase I poison-induced G2/M checkpoint in p53-null tumor cells by depleting Chk1 and Wee1.Uracil in DNA: consequences for carcinogenesis and chemotherapyActivation of ATM/Chk1 by curcumin causes cell cycle arrest and apoptosis in human pancreatic cancer cells
P2860
Q21245716-E1499170-FDD8-46AF-BE88-0C16A0559483Q24657439-9E8F4B6B-F693-44C1-8FF4-19885C153819Q28485896-BEBB6450-8BA3-4B9E-BCA4-4AA448EE8874Q30002343-386C66B0-8927-428E-8CBE-402D590B6D7FQ30422919-BD039240-8710-4192-A4EB-462FCD7E66C3Q30495277-4F873B1B-8C95-4F68-B4C3-3A9C3B057791Q33400687-91CC7FD8-E988-4517-A438-A2A7A3256A24Q33474752-18E2B9E6-138C-4572-94A0-D49E5236DA9EQ33794733-8ED39838-BB10-490E-9046-84B2C64F7929Q33912171-E050424B-5354-4F3C-B4CE-C8E05FE69FC7Q33932866-000B7FE7-19F8-4C40-B8FD-294F48530FDBQ33983255-2A7DA9ED-B1D2-4D2F-898A-4B27C7B1CFB0Q34129155-310B2BA7-40BB-41EC-A72E-FA753AE584CAQ34236709-ACA6BF85-FA6B-49F2-87E7-07EDB85FFB06Q34240365-0D5447A6-58D7-4720-AB3A-59918882D97CQ34300057-1E2B8011-AF7A-4C37-9F9B-51294E54ABE1Q34667764-9664DD68-926E-4B02-8AC3-BCBD158E38AFQ34760619-A55D5A78-EBBB-4DD4-AA01-4231961796E4Q35385267-82F3F4FF-A9DF-4707-AC35-9F791274ACDDQ35630615-DE78F302-EE1E-4AFA-9EFF-AA00D368C884Q35667126-9F960940-610B-4E72-9179-7A281AA4D152Q35678658-CAB1B6FB-537B-4F69-A4C1-3A787F8D7FCDQ35750491-BE859D6F-D785-4F94-964A-CC87FF663AD3Q35858051-63D60E4A-FDD3-4A01-A63B-4AEA4641FA02Q36035102-5CB4E0B7-4A01-423B-BEAB-53C65EF0F4C5Q36289902-36DF1112-9665-4957-A51A-A921B5EE0ED8Q36291178-C338B83F-C2E5-41BD-AF42-86ED215D2D7AQ36405766-CFE78014-8AC3-4ECE-ADC7-B3F5E9D6427FQ36737314-E4CD2993-A8F1-4433-9EDC-0AB8CBAE883EQ36792626-1AEA8211-CDC4-4246-A6F6-081C2045B140Q36868759-F68E213F-37FB-40A9-A86E-699C4DD1567FQ36901517-64FE883D-8F75-4444-9599-6891BD8AA681Q37046021-F7A2068A-2F60-44A2-B43F-3C50A6C74001Q37071564-1513A127-34D4-46F8-B1B3-272FB03867D5Q37114275-B4E563E8-A423-42A6-B025-68FD9EF214C1Q37135359-F30BF1E4-EB99-4F1F-A099-D5A3A03BFDEDQ37168650-150A24F2-A575-4B3F-94AD-1329AAF5E702Q37199458-28BF081E-4181-45D5-A4F6-E2195FC8DE7EQ37206564-FE846989-5E0F-437C-B88C-0DB60C70A565Q37222677-C0D4A6ED-2320-4D69-8C50-C9DDA0315B38
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Targeting checkpoint kinase 1 in cancer therapeutics.
@ast
Targeting checkpoint kinase 1 in cancer therapeutics.
@en
type
label
Targeting checkpoint kinase 1 in cancer therapeutics.
@ast
Targeting checkpoint kinase 1 in cancer therapeutics.
@en
prefLabel
Targeting checkpoint kinase 1 in cancer therapeutics.
@ast
Targeting checkpoint kinase 1 in cancer therapeutics.
@en
P2093
P1476
Targeting checkpoint kinase 1 in cancer therapeutics.
@en
P2093
Archie N Tse
Gary K Schwartz
Richard Carvajal
P304
P356
10.1158/1078-0432.CCR-06-2793
P407
P577
2007-04-01T00:00:00Z